Editas Medicine, Inc. Common Stock (EDIT)

Price$3.34

Value ScoreD

Growth ScoreD

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)24.15%

Price vs S&P 500 (4W)14.34%

VGM Score48.49

Market Capitalization$338.76M

All Metrics

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)2.40x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)27.15%

Cash Flow / Share (Quarterly)$-1.44

Price vs S&P 500 (YTD)57.85%

Net Profit Margin (TTM)-281.59%

EPS (TTM)$-1.22

10-Day Avg Trading Volume4.24M

EPS Excl Extra (TTM)$-1.22

Revenue Growth (5Y)-14.89%

EPS (Annual)$-1.80

ROI (Annual)-186.35%

Net Profit Margin (5Y Avg)-639.39%

Cash / Share (Quarterly)$1.26

Revenue Growth QoQ (YoY)-39.22%

ROA (Last FY)-85.81%

Revenue Growth TTM (YoY)7.97%

EBITD / Share (TTM)$-1.14

ROE (5Y Avg)-180.58%

Operating Margin (TTM)-281.32%

Cash Flow / Share (Annual)$-1.69

P/B Ratio76.85x

P/B Ratio (Quarterly)54.84x

Net Income / Employee (Annual)$-1,839,800

EV / Revenue (TTM)6.97x

Net Interest Coverage (TTM)-121.78x

ROA (TTM)-58.25%

EPS Incl Extra (Annual)$-1.80

Current Ratio (Annual)3.54x

Quick Ratio (Quarterly)3.17x

3-Month Avg Trading Volume1.90M

52-Week Price Return89.07%

Revenue / Employee (TTM)$444,700

Tangible BV / Share (Quarterly)$4.41

P/S Ratio (Annual)8.36x

Asset Turnover (Annual)0.22x

52-Week High$4.54

Operating Margin (5Y Avg)-658.26%

EPS Excl Extra (Annual)$-1.80

CapEx CAGR (5Y)-38.95%

Tangible BV CAGR (5Y)11.63%

26-Week Price Return40.08%

Quick Ratio (Annual)3.50x

13-Week Price Return58.72%

Total Debt / Equity (Annual)2.15x

Current Ratio (Quarterly)3.22x

Enterprise Value$269.78M

Revenue / Share Growth (5Y)-21.67%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-46.38%

Revenue / Employee (Annual)$465,700

Pretax Margin (Annual)-395.01%

Cash / Share (Annual)$1.50

3-Month Return Std Dev90.98%

Net Income / Employee (TTM)$-1,252,300

ROE (Last FY)-586.56%

Net Interest Coverage (Annual)-43.22x

EPS Basic Excl Extra (Annual)$-1.80

Receivables Turnover (TTM)24.95x

Total Debt / Equity (Quarterly)12.40x

EPS Incl Extra (TTM)$-1.22

Receivables Turnover (Annual)2.58x

ROI (TTM)-148.56%

P/S Ratio (TTM)8.76x

Pretax Margin (5Y Avg)-639.39%

Revenue / Share (Annual)$0.46

Tangible BV / Share (Annual)$5.24

Price vs S&P 500 (52W)60.86%

Year-to-Date Return68.78%

5-Day Price Return25.36%

EPS Normalized (Annual)$-1.80

ROA (5Y Avg)-51.44%

Net Profit Margin (Annual)-395.01%

Month-to-Date Return15.33%

Cash Flow / Share (TTM)$-2.60

EBITD / Share (Annual)$-1.74

Operating Margin (Annual)-394.89%

LT Debt / Equity (Annual)1.96x

ROI (5Y Avg)-89.96%

LT Debt / Equity (Quarterly)10.70x

EPS Basic Excl Extra (TTM)$-1.22

P/TBV (Quarterly)2.40x

P/B Ratio (Annual)7.33x

Pretax Margin (TTM)-281.59%

Book Value / Share (Annual)$0.28

Price vs S&P 500 (13W)48.97%

Beta2.13x

Revenue / Share (TTM)$0.40

ROE (TTM)-677.39%

52-Week Low$1.66

vGradeD

gGradeD

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.26est. -0.27

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.70

3.75

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
EDITEditas Medicine, Inc. Common Stock	D	D	A	$3.34
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Editas Medicine is a clinical-stage genome editing company developing CRISPR/Cas9-based therapeutics to treat serious genetic diseases. The company's proprietary platform uses a Cas9 enzyme-guide RNA complex to precisely repair disease-causing DNA mutations. Editas is advancing a pipeline of genome editing programs toward clinical and commercial applications.